Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

NCT01888562 · clinicaltrials.gov ↗

NA

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Could not obtain an IDE on the FGFR2 assay

Conditions

Endometrial Neoplasms

Interventions

DRUG: Ponatinib

Sponsor

Washington University School of Medicine